Overview

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-08-31

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to understand the effectiveness of dostarlimab and carboplatin-paclitaxel followed by dostarlimab monotherapy in participants with endometrial cancer

Phase:

PHASE2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Carboplatin
dostarlimab
Paclitaxel